Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 102.85%.

  • Lineage Cell Therapeutics' EBITDA Margin fell 12400.0% to 102.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 325.27%, marking a year-over-year decrease of 645700.0%. This contributed to the annual value of 226.11% for FY2024, which is 503900.0% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its EBITDA Margin stood at 102.85% for Q3 2025, which was down 12400.0% from 715.37% recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year EBITDA Margin high stood at 56.48% for Q4 2021, and its period low was 1803.07% during Q1 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 301.45% (2021), whereas its average is 419.31%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 16809400bps in 2022, then crashed by -3629700bps in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' EBITDA Margin (Quarter) stood at 56.48% in 2021, then crashed by -514bps to 346.68% in 2022, then rose by 12bps to 304.69% in 2023, then surged by 42bps to 178.17% in 2024, then soared by 42bps to 102.85% in 2025.
  • Its last three reported values are 102.85% in Q3 2025, 715.37% for Q2 2025, and 433.09% during Q1 2025.